Fan (Frank) Yu, Chief Executive Officer and Director

Fan (Frank) Yu has been our Chief Executive Officer and a Director since November 2020.  Mr. Yu is the founder, Chief Executive Officer and Chief Investment Officer of Ally Bridge Group, a global life science-dedicated investment group.  Prior to founding Ally Bridge Group’s predecessor company in 2009, Themes Investment Partners, Mr. Yu was a Managing Director and Head of China Investments at Sculptor Capital Management (formerly Och-Ziff Capital Management) from 2007 to 2009.  Prior to that, Mr. Yu spent nearly a decade at Goldman Sachs in Hong Kong, initially in Credit Risk Management and then Investment Banking Division as a Managing Director, where he advised companies on restructuring, financing and mergers and acquisitions.  Before Goldman Sachs, Mr. Yu worked at Moody’s in New York and then at Credit Suisse in London and Hong Kong.  In addition, Mr. Yu has been a director at Artisan Acquisition Corp. since May 2021 and was a director of Atea Pharmaceuticals, Inc. from August 2016 to December 2019 and currently serves on the Board of Trustees to the Solomon R. Guggenheim Foundation and on the Advisory Board to the Hong Kong Life Sciences Society. Mr. Yu holds a bachelor’s degree in Economics and Applied Mathematics from Queens College of the City University of New York.

Kevin Reilly, Chief Financial Officer and Director

Kevin Reilly serves as our Chief Financial Officer and Director. Mr. Reilly, joined Ally Bridge Group in 2021 and is currently a managing director focused on private equity strategies in healthcare market sectors. Before joining Ally Bridge Group, Mr. Reilly was a principal focused on medical technology investments at CRG, L.P., a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity, beginning in 2014. Mr. Reilly began his career in 2012 in the Healthcare Investment Banking Group at Stifel, Nicolaus & Company, Inc. Mr. Reilly holds a Bachelor of Science degree in Finance and Information Systems from the University of Maryland.

Jean-Pierre Sommadossi, Ph.D.

Jean-Pierre Sommadossi, Ph.D., is a member of our board of directors. Dr. Sommadossi is the founder of Atea Pharmaceuticals (Nasdaq: AVIR), where he has served as the Chairman & CEO since 2012. He has over 30 years of scientific, operational, strategic and management experience in the biotech industry. Prior to founding Atea Pharmaceuticals in 2012, Dr. Sommadossi was the Principal Founder of Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), which was acquired by Merck & Co., Inc. (NYSE: MRK) for $3.85 billion in 2014, and a Co-Founder of Pharmasset, Inc. (Nasdaq: VRUS), which was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) for $11 billion in 2012. Dr. Sommadossi held a number of significant executive positions at Idenix, including Chairman of the Board of Directors, Executive President and Chief Scientific Officer from 1998 to 2000, and then as Chairman and Chief Executive Officer from 2000 to 2010. Under his leadership, Idenix entered into multiple strategic collaborations, including those with Sumitomo and GlaxoSmithKline (GSK), as well as a landmark biotech-pharma transaction with Novartis Pharma AG in 2003. During his tenure, Idenix discovered, co-developed and co-launched telbuvidine (Tyzeka/Sebivo) for the treatment of hepatitis B, and established a major clinical pipeline of antiviral therapeutics for the treatment of hepatitis C and HIV/AIDS. Dr. Sommadossi is also the Chairman of Kezar Life Sciences, Inc. (Nasdaq: KZR) and Panchrest, Inc., and a member of the Board of The BioExec Institute.

Stuart Chaffee, Ph.D.

Stuart Chaffee, Ph.D., is a member of our board of directors. Dr. Chaffee was the Chief Financial Officer of Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, from June 2020 to December 2020 and its Chief Business Officer from November 2017 to June 2020, responsible for the company’s business development, finance and operational activities. From November 2015 to November 2017, Dr. Chaffee was an Entrepreneur in Residence at Atlas Venture, where he was a co-founder and the Head of Business Operations at Kymera Therapeutics, Inc. from June 2016 to November 2017.

Robert Castro, CPA, CGMA

Robert Castro, CPA, CGMA, is a member of our board of directors. Mr. Castro is the owner of Savvy Fare LLC, an accounting and consulting firm that he founded in July 2010. Prior to that, Mr. Castro was a managing director at BDO Seidman LLP, where he began his career in December 1980, served as an auditor and advisor for many public companies, and led and participated in numerous IPOs. Mr. Castro is a Certified Public Accountant and Chartered Global Management Accountant.